NCT07144137招募中不适用
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Complement Therapeutics17 个研究点 分布在 2 个国家目标入组 75 人开始时间: 2025年7月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 75
- 试验地点
- 17
- 主要终点
- Short-term GA Progression
研究概览
简要总结
This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years.
This is a multi-center, non-interventional, observational study which aims to identify participants who have progressive GA to allow quantification of structural and functional parameters that characterize the progression of GA, and to investigate whether these correlate with genetic or lifestyle factors.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must be aged ≥55 years, at the time of signing the informed consent at the screening visit.
- •Participants with bilateral GA secondary to AMD as confirmed by the Central Reading Center using FAF and/or OCT images with at least 1 eye having a total GA lesion area must be between 1.25 mm2 and 17.5 mm2 inclusive, determined by FAF images taken at the screening visit.
- •Best-corrected visual acuity (BCVA) in both eyes should be sufficient to ensure navigational vision (defined as 20/400 or better for purposes of this study).
- •BCVA between 20 and 75 letters and LLVA>0 letters using an ETDRS chart.
- •Mean retinal sensitivity as measured by microperimetry using the study grid must be equal to or greater than 5 dB.
- •Able and willing to provide signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, and in the opinion of the investigator, is able to perform all study assessments.
排除标准
- •Macular atrophy secondary to any condition other than AMD in the study eye.
- •Any pathology of the macula other than GA secondary to AMD and other changes consistent with early, intermediate or atrophic AMD in the study eye.
- •Evidence of prior or current Choroidal Neovascularization (CNV), also known as wet-AMD, in either eye.
- •Atrophic retinal disease of causality other than AMD including monogenetic macular dystrophies (incorporating pattern dystrophy), myopia-related maculopathy and Stargardt disease in the study eye.
- •A history of vitrectomy in the study eye.
- •Any prior treatment for AMD or any prior intravitreal treatment for any indication in the study eye, except oral supplements of vitamins and minerals such as the age-related eye disease study (AREDS) formula.
- •Any intraocular surgery (except cataract surgery within 6 months of enrollment) or thermal laser within 3 months of screening, or any ophthalmic condition that may require surgery during the study.
- •Any macular laser, macular surgery or retinal surgery at any time point in the study eye.
- •Any ocular or periocular infection in the 12 weeks prior to screening.
- •History of uveitis or endophthalmitis in either eye.
- •Any sign of diabetic retinopathy in either eye, or HbA1c >8, in the 12 months prior to enrollment.
- •High myopia or hyperopia (≥6 diopter) in the study eye.
- •Uncontrolled IOP measurement of ≥25 mmHg for >1 month despite being on 2 or more ocular hypotensive agents, or IOP >21 mm Hg in the presence of C/D asymmetry of >0.3 per the reading center; or glaucomatous damage to the optic nerve or visual field.
- •Retinal disease other than AMD or other ocular disorders which may cause safety concerns per the judgment of the investigator; however, benign conditions of the vitreous or peripheral retina are not exclusionary (i.e., paving stone degeneration).
- •Any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the investigator interferes with ophthalmologic examination (e.g., cataract or corneal abnormalities) either at the time of enrollment or during the 2-year post dosing follow-up period; or prevents adequate imaging of the retina judged by the site or CRC.
- •Aphakia or absence of the posterior capsule. Previous violation of the posterior capsule is also excluded unless it occurred as a result of yttrium aluminum garnet (YAG) laser posterior capsulotomy in association with prior posterior chamber intraocular lens implantation and at least 60 days prior to baseline.
- •Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up over the treatment period unlikely, or in general a poor medical risk because of other systemic diseases or active uncontrolled infections, including but not limited to immunodeficiency state, autoimmune diseases, malignancy other than prostate or basal cell carcinoma, connective tissue disorders and collagen vascular disorders.
- •Participation in an interventional clinical study, or use of any experimental treatment for AMD or any investigational product within 6 months or 5 half-lives of the active ingredient (whichever is longer) prior to screening.
- •History of abnormal laboratory tests (e.g. hematology, serum chemistry, renal or liver function tests, or infectious disease screen) that in the opinion of the investigator is clinically significant at the time of enrollment and not suitable for study participation.
- •Hypersensitivity to medications used in (standard of care) study procedures.
- •Situations where, in the opinion of the investigator, the risk of harm to a participant outweighs any potential benefits from study participation (these could include participants with conditions such as brittle diabetes or advanced osteoporosis as examples).
- •History or current use of medications associated with macular changes, retinal dysfunction or optic nerve damage. These include but are not limited to the following prohibited concomitant medications:
- •Any previous gene or cell therapy (ophthalmic or systemic),
- •Chloroquine (where taken for >30 days cumulative across participant's lifetime), hydroxychloroquine, platinum containing medications, ethambutol, tamoxifen, pentosan, chronic use of phosphodiesterase inhibitors, and GLP-1 antagonists in the setting of a crowded optic disc.
结局指标
主要结局
Short-term GA Progression
时间窗: Baseline, Month 3, Month 6
To quantify the structural and functional parameters of short-term progression of geographic atrophy (GA) through clinical evaluation and investigations
次要结局
- Further exploration of GA progression(Baseline, Month 3, Month 6)
研究者
研究点 (17)
Loading locations...
相似试验
招募中
不适用
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in GermanyEosinophilic EsophagitisNCT06695897Sanofi150
已完成
不适用
Long-term Follow-up Observation After Surgical Treatment of Peri-implantitis in Multicenter Post Market Clinical StudyPeri-implantitisNCT03776097Geistlich Pharma AG59
进行中（未招募）
4 期
This non-interventional observational study (CRAD001H2406) is to evaluate recurrence of hepatocellular carcinoma (HCC) until Month 60 post-transplantation in liver transplant recipients with primary HCC at liver transplantatioCTRI/2019/10/021760ovartis Healthcare Pvt Ltd1
已完成
Unknown
An Observational study to check safety and effectiveness of CASIRIVIMAB/ IMDEVIMAB treatment of mild/moderate covid 19 patients in IndiaCoronavirus as the cause of diseases classified elsewhere,CTRI/2021/06/034375Roche Products India Pvt Ltd200
已完成
不适用
An Observational Study in Adult Patients With Non-dystrophic Myotonic DisordersMyotonic DystrophyNCT04616807Lupin Ltd.53